Fig. 5

Fig. 5

Effects of doxorubicin and epirubicin on proliferation and apoptosis in the hyperplastic livers of transgenic zebrafish larvae. (A) An example of the whole liver after dissection in both bright-field and fluorescent images. Scale bars: 50 μm. (B) Representative images of BrdU and TUNEL staining in the DMSO-, doxorubicin- and epirubicin-treated zebrafish liver with EGFP-kras^G12V over-expression. Scale bars: 10 μm. (C) Statistics of the DMSO-, doxorubicin- and epirubicin-treated liver size from the transgenic larvae (n=16). The values are means±s.e.m., with statistical differences being determined by one-way ANOVA, ***P<0.001; NS, not significant. (D) Statistics of BrdU and TUNEL labelling in the DMSO-, doxorubicin- and epirubicin-treated zebrafish liver with EGFP-kras^G12V over-expression (n=16). The values are means±s.e.m., with statistical differences being determined by one-way ANOVA; *P<0.05, ***P<0.001; NS, not significant. (E) The cytotoxicity of doxorubicin and epirubicin in the liver cancer cells BEL7402 and Huh7 using the MTT assay. The dashed lines are the IC₅₀ values for each compound. (F) The statistical results of the IC₅₀ of doxorubicin and epirubicin in the liver cancer cells BEL7402 and Huh7. The values are means±s.e.m., with statistical differences being determined by Student's t-test; *P<0.05, ***P<0.001.